BridgeBio Pharma, Inc. — Director's Dealing 2020

Nov 19, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-11-16

Reporting Person: HENDERSON MICHAEL THOMAS (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-16	Common Stock	M	10000	$1.05	Acquired	277751	Direct
2020-11-16	Common Stock	S	10000	$45.00	Disposed	267751	Direct
2020-11-16	Common Stock	M	12813	—	Acquired	280564	Direct
2020-11-16	Common Stock	F	6353	$44.33	Disposed	274211	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-16	Stock Option (Right to Buy)	$1.05	M	10000	Disposed	2029-09-24	Common Stock (10000)	Direct
2020-11-16	Restricted Stock Units	$	M	12813	Disposed		Common Stock (12813)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020.

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F3: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 12,813 shares of Common Stock underlying the Reporting Person's RSUs.

F4: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.